Text and Data Mining valid from 2019-11-01
Received: 22 July 2019
Accepted: 14 October 2019
First Online: 1 November 2019
Ethics approval and consent to participate
: The research study received approval from the Northwell Health Institutional Review Board (FWA# 00002505), and is being conducted in adherence to the approval as IRB study number 17–0070. All study participants provided written informed consent prior to the initiation of any research procedures.
: All study participants provided written informed consent for publication as part of their consent for participation in the research study. Additionally, separate audio and visual authorization was provided for the utilization of images and video in publication.
: CEB holds various patents in the bioelectronic medicine field and is a shareholder in Sanguistat, a company focused on bleeding reduction/suppression, and is a founder and shareholder of Neuvotion, LLC, a company focused on movement restoration in paralysis, related to the reviewed work.